Business Wire · RHHBF · November 16, 2026
FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer

Get the app for more
Explore stock news, insights and company research.
Get the app → Source: Business Wire ↗